Related Experiment Video
Updated: Jul 31, 2025
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.0K
Parkinson's disease therapy: what lies ahead?
Andreas Wolff1, Nicolas U Schumacher1, Dominik Pürner1
1Department of Neurology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, Germany.
Summary
Parkinson's disease (PD) treatment is advancing, with new drugs and telehealth improving care. Future therapies aim to modify disease progression, not just symptoms, offering hope for better outcomes.
Area of Science:
- Neurology
- Pharmacology
- Gerontology
Background:
- Parkinson's disease (PD) prevalence is rising globally, increasing the need for effective treatments.
- Current PD management focuses on symptomatic relief, primarily dopaminergic stimulation.
- Longer disease duration due to increased life expectancy necessitates improved patient care and socioeconomic support.
Purpose of the Study:
- To review recent advancements in Parkinson's disease therapy.
- To explore emerging strategies for modifying PD progression.
- To provide insights into the future of PD treatment.
Main Methods:
- Review of current literature on Parkinson's disease treatments.
- Analysis of recent developments in drug formulations and delivery.
- Examination of novel clinical trial designs and therapeutic targets.
Main Results:
- Improved patient care through new drug formulations and telehealth monitoring.
- Identification of novel pharmacological targets based on enhanced understanding of PD mechanisms.
- Progress in developing disease-modifying therapies and targeting earlier disease stages.
Conclusions:
- Recent advancements offer improved symptomatic management for Parkinson's disease.
- Future Parkinson's disease therapies hold promise for disease modification.
- Addressing PD heterogeneity and employing novel trial designs are key to future treatment success.
Related Concept Videos
01:24Parkinson's Disease: Treatment
315
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
315
01:15Parkinson's Disease: Overview
624
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
624
01:21EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
01:22Alzheimer's Disease: Treatment
230
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
230
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:28Drug Therapy
76
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
76